About Echosens north america
Echosens North America: Revolutionizing Liver Disease Management with FibroScan®
Echosens North America is a leading medical technology company that specializes in the development and manufacturing of FibroScan®, a non-invasive solution for the accurate measurement of liver stiffness and liver steatosis. The company's mission is to provide healthcare professionals with innovative tools that enable them to better manage liver disease, improve patient outcomes, and reduce healthcare costs.
Liver disease is a growing global health concern, affecting millions of people worldwide. It can be caused by various factors such as alcohol abuse, viral hepatitis, obesity, and metabolic disorders. Early detection and management are crucial in preventing the progression of liver disease to more severe conditions such as cirrhosis or hepatocellular carcinoma.
FibroScan® is an advanced diagnostic tool that uses patented Vibration-Controlled Transient Elastography (VCTE) technology to measure liver stiffness non-invasively. The procedure involves placing a small probe on the skin overlying the liver area while the patient lies on their back. The probe emits low-frequency vibrations that generate shear waves in the liver tissue. These waves are then measured by sensors in the probe to determine the degree of stiffness or fibrosis present in the liver.
FibroScan® also measures Controlled Attenuation Parameter (CAP), which assesses fat accumulation or steatosis in the liver. This information provides clinicians with valuable insights into patients' overall hepatic health status and helps guide treatment decisions.
One of FibroScan®'s key advantages over traditional methods such as biopsy is its non-invasive nature, which eliminates many risks associated with invasive procedures such as bleeding or infection. Additionally, FibroScan® provides immediate results without requiring hospitalization or anesthesia.
Echosens North America has been at the forefront of developing innovative solutions for managing chronic liver diseases since 2001 when it was founded by Drs Laurent Sandrin and Jonel Trebicka. The company has a global presence, with offices in Europe, Asia, and North America.
FibroScan® has been extensively validated in numerous clinical studies worldwide and is recognized as a reliable tool for assessing liver stiffness and steatosis. It is recommended by major international guidelines for the management of liver disease such as the European Association for the Study of Liver (EASL) and the American Association for the Study of Liver Diseases (AASLD).
Echosens North America's commitment to innovation extends beyond FibroScan®. The company also offers complementary solutions such as FibroView®, a software application that enables clinicians to view and interpret FibroScan® results remotely, enhancing patient care coordination.
In conclusion, Echosens North America is a leading medical technology company that provides healthcare professionals with innovative tools to manage chronic liver diseases effectively. Its flagship product, FibroScan®, is an advanced diagnostic tool that uses non-invasive VCTE technology to measure liver stiffness and steatosis accurately. With its commitment to innovation and patient care coordination, Echosens North America continues to revolutionize how we manage chronic liver diseases globally.